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I. Abstract 
Previous research using the chicken model has provided evidence that a flaxseed-
supplemented diet decreases both the severity and the incidence of ovarian cancer. Flaxseed is a 
source of omega-3 (OM3) polyunsaturated fatty acids (PUFA), particularly α-linolenic acid 
(ALA). ALA is converted into longer chain OM3s, eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA), which inhibit prostaglandins, thereby inhibiting oxidative stress, 
inflammation, angiogenesis, and proliferation. The dietary fiber component of flaxseed can be 
fermented in the gut to produce short chain fatty acids (SCFA). Butyric acid, a commonly studied 
SCFA, has been shown be an important metabolic regulator by acting as a histone deacetylase 
(HDAC) inhibitor, a transcriptional modulator, as well as an anti-inflammatory molecule. In order 
to determine whether or not PUFA and butyric acid are upregulated by flaxseed supplementation 
in the chicken ovaries, the concentrations of each were quantified using gas chromatographic 
analysis. The amount of fatty acids in each sample were normalized to total protein content. Hens 
on a flaxseed-supplemented diet displayed an increase in the ratio of OM3:OM6 PUFA when 
compared to the control diet. Likewise, the concentrations of butyric acid were also increased in 
ovaries of hens fed a flaxseed-supplemented diet in comparison to hens that were fed a control 
diet. Moreover, butyric acid was significantly decreased in both the ovaries and ceca by ovarian 
cancer. These observations give us insight into the possible role of flaxseed in modulating 
metabolic activity through an upregulation of SCFA and OM3 PUFA in the ovaries.  
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II. Introduction  
 With nearly 22,000 new cases each year, and 14,000 of those cases leading to death, 
epithelial ovarian cancer (EOC) is the most lethal among all other gynecologic malignancies 
(“Ovarian Cancer Statistics,” 2019). Ovarian cancer usually reaches stage 3 or 4 by the time it is 
diagnosed due to insufficient screening mechanisms and lack of symptoms early in the disease. 
For this reason, ovarian cancer has been termed the ‘silent killer,’ and is treated, perhaps most 
effectively, through prevention. Advancement in the treatment and prevention of ovarian cancer 
has been hindered in the past due to the lack of a functional animal model, but has recently begun 
to move forward with the introduction of the chicken model. EOC develops spontaneously in the 
White Leghorn Laying Hen and closely resembles the human form of the disease. Studies 
performed using the chicken model provide the opportunities to conduct large scale dietary 
intervention studies in a timely manner due to the fact that 2-year-old White Leghorn Hens ovulate 
300-400 times, nearly the same as a perimenopausal woman, and similarly to humans, the risk of 
developing the disease and the severity of the disease for the laying hens increases with age.  
 In previous study conducted in Dr. Hales’ lab, hens fed a 10% flaxseed-supplemented diet 
for four years displayed a significant decrease in incidence and severity of ovarian cancer (Eilati, 
Bahr et al. 2013), pointing at the possibility of flaxseed acting as a regulator of metabolic activity 
and gene expression. Flaxseed is a dietary fiber made up of two major components: omega-3 
(OM3) polyunsaturated fatty acids (PUFA) and phytoestrogen lignin (SDG). OM3 PUFA provide 
anti-oxidant, anti-inflammatory, anti-angiogenic, and apoptotic effects, thereby preventing cancer 
development by inhibiting the actions of prostaglandins. Similarly, SDG is converted into 
enterodiol (ED) and enterolactone (EL), which prevent cancer development by blocking 
proliferation and mutagenesis via estrogen inhibition. This study was designed specifically to 
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explore the role of the fatty acid component of flaxseed by measuring OM3 PUFA levels in 
comparison to omega-6 (OM6) PUFA, as well as exploring the effects of flaxseed-supplementation 
on prostaglandin synthesis.  The dietary fiber component of flaxseed was also investigated by 
measuring short chain fatty acid (SCFA) levels in the ovaries to demonstrate possible mechanisms 
of flaxseed acting as a metabolic regulator in ovarian cancer. 
 OM3 PUFA are considered essential fatty acids because they cannot be produced in the 
body, and therefore must be consumed by the diet. OM3 PUFA include stearadonic acid (SDA) 
(C18:4), alpha-lenolenic acid (ALA) (C18:3), and eicosapentanoic acid (EPA) (C20:5) and 
docosahexanoic acid (DHA) (C22:6), which are two byproducts of ALA. ALA serves a variety of 
purposes throughout the body, including reducing inflammation, promoting blood vessel health 
via incorporation into cell membranes, and being converted into the longer chain OM3 PUFA- 
EPA and DHA (Licastro, Candore et al. 2005). The ability for ALA to be converted into EPA and 
DHA is dependent upon diet. By reducing inflammation, ALA helps prevent and manage type 2 
diabetes, heart disease, kidney disease, and many other chronic diseases, including some cancers, 
and by promoting blood vessel function, it also reduces the risk of heart attacks and stroke 
(Licastro, Candore et al. 2005). In addition, ALA produces energy for muscles by undergoing β-
oxidation, can be used to make ketone bodies, and is stored in adipose tissue to serve as a reserve 
supply of energy.  
 ALA itself, however, does not have as many well described health benefits as EPA and 
DHA, but once consumed by the diet, ALA can be converted into these longer chain PUFA through 
a series of steps occurring in the endoplasmic reticulum, which involve alternating desaturations 
and elongations. Desaturase enzymes add double bonds to the fatty acids by removing hydrogen, 
while elongase enzymes add two additional carbons. ALA metabolism begins with desaturation 
Ochs 5 
 
 
  
via delta-6-desaturase enzyme, forming SDA. This step is rate limiting because it is dependent on 
nutrition, hormones, and metabolism. The process of desaturation is very slow in comparison to 
the rapid process of elongation, so SDA is usually found in very low concentrations because once 
it is formed, it is quickly elongated to 20:4n3 (Licastro, Candore et al. 2005). 20:4n3 is then 
desaturated by delta-6-desaturase enzyme to produce EPA, which is also quickly elongated, 
forming docasapentaenoic acid (DPA) (C22:5). DPA is found in very trace amounts, as it is also 
quickly elongated to form 24:5n3. 24:5n3 then gets desaturated again, forming 24:6n3, which is 
finally β-oxidized to produce the end product of ALA metabolism: DHA (Licastro, Candore et al. 
2005). Because this is the final step, DHA is often present in larger concentrations than the other 
OM3 PUFA. Following the metabolism of ALA, EPA and DHA can be incorporated throughout 
the body and further contribute to the viscosity of cell membranes, alterations in immune and 
tumor cell function, anti-inflammatory actions, and treatment or prevention of various diseases, 
such as cancer and cardiovascular disease (Swanson, Block et al. 2012). However, ALA 
metabolism does not always make it all the way to DHA. Some factors that can affect the 
conversion of ALA to EPA, DPA, and DHA include gender, smoking, and diet (Licastro, Candore 
et al. 2005). Cigarette smoke has been shown to reduce the conversion of ALA to EPA and DHA. 
Men also show a reduced metabolism of ALA compared to women, who are likely more sensitive 
to diet than women due to their unique hormonal profile. Women’s increased ability to convert 
ALA to DHA is very important during pregnancy and breast feeding (Licastro, Candore et al. 
2005). Lastly, a diet that is rich in OM6 PUFA significantly decreases the conversion of ALA, in 
addition to diets that are high in saturated fats, oleic acid, trans fatty acids, and cholesterol, which 
disrupt the actions of desaturase and elongase enzymes (Licastro, Candore et al. 2005). These 
factors suggest that ALA conversion is very dependent on one’s individual metabolic capacity. If 
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dietary flaxseed increases the levels of OM3 PUFA compared to OM6 PUFA, and therefore 
increases the levels of DHA converted from ALA, this could demonstrate one mechanism in which 
flaxseed works to improve overall metabolism could be revealed.  
OM6 PUFA, like OM3, are essential fatty acids and must be consumed from the diet. 
However, because these two groups of fatty acids cannot interconvert between one another, there 
is competition between the metabolism of the two (Licastro, Candore et al. 2005). Excess of one 
can affect the metabolism of the other because they use similar mechanisms, involving the same 
desaturase and elongase enzymes. OM6 PUFA are typically consumed much more abundantly 
than OM3, and primarily include linoleic acid (LA) (C18:2) and arachidonic acid (AA) (C20:4). 
LA consumed from the diet is desaturated to produce gamma-linolenic acid (GLA) (C18:3). GLA 
is elongated, forming dihomo-gamma-linolenic acid (DGLA) (C20:3). This fatty acid is 
desaturated to make AA, which is elongated and desaturated to eventually form DPA following β-
oxidation. AA is known to be the primary source for prostaglandins. Prostaglandins consist of a 
20-carbon, unsaturated fatty acid chain and are synthesized via the cyclooxygenase (COX1 and 
COX2) pathway (Chen, Wang et al. 2019). Prostaglandins can be harmful by causing 
inflammation, oxidative stress, angiogenesis, and proliferation. The action of prostaglandins can 
be inhibited by increasing the levels of OM3 PUFA, which will use the enzymes needed by OM6 
PUFA to produce AA. By decreasing the 
amount of AA converted from LA, the levels 
of prostaglandins will also be reduced. By 
showing a negative correlation between 
dietary flaxseed and AA / prostaglandin 
synthesis, another mechanism in which 
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flaxseed has the ability to improve metabolic activity, specifically by regulating inflammation and 
oxidative stress, could be observed. 
 The relationship between diet and gut microbiota strongly influences metabolic health by 
the bacterial synthesis of various metabolites, such as SCFA, which are fermented by bacteria in 
the gut from dietary fibers. Different dietary fibers are fermented differently based on fiber 
structure, which could favor or disfavor growth, and type of bacteria, which have varying 
metabolites that alter the gut microenvironment in different ways (Bishehsari, Engen et al. 2018). 
Pleiotropic effects, including immune system modulation, anti-inflammatory effects, and 
alterations in pathogen susceptibility, have been associated with an upregulation of SCFA, such as 
acetate, propionate, and butyrate (Shubham, Chakravarty et al. 2019). For this reason, SCFA are 
being studied as a possible preventative mechanism for various diseases, and in this case, ovarian 
cancer.  
 One SCFA in particular, butyric acid (C4:0), has been previously reported to have an 
exceptionally beneficial role in immunity. The SCFA facilitates an immune response by altering 
various catabolic processes in human cells and by modulating gene expression by acting as an 
HDAC inhibitor (Shubham, Chakravarty et al. 2019). HDAC inhibitors favor histone acetylation, 
resulting in an open and transcriptionally active form of chromatin. Through its HDACi activity, 
butyric acid has been shown to improve insulin signaling by upregulating the expression of IRS1, 
protect against oxidative stress linked to the over-expression of FOXO3a and PGC-1α,  (Chriett, 
Dabek et al. 2019). In addition, butyric acid upregulates the activity of various mitochondrial 
genes, including the mitochondrial sirtuins (SIRT3, 4, and 5) responsible for regulation of 
mitochondrial activity, SOD2, and CPT1b, and also contributes to the expression of catalase, 
which functions in cell defense, especially against oxidative stress (Chriett, Dabek et al. 2019). All 
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of these genes are upregulated by butyric acid and function to improve cellular immunity, protect 
against oxidative stress, and regulate mitochondrial activity, enhancing overall metabolic activity 
and protecting the body from various diseases. Thus, identifying whether SCFA, in particular 
butyric acid, are upregulated by a flaxseed supplemented diet could provide insight into one 
mechanism for preventing or reducing the severity of ovarian cancer.  
The objective for the current study was to better understand the role of dietary flaxseed in 
regulating metabolic activity and gene expression by exploring the levels of PUFA and SCFA in 
the ovaries collected from White Leghorn laying hens. The 2-year old hens were placed on one of 
six diets, four of which were flax based diets, and are outlined below in Table 1. The other two 
diets included fish oil and corn oil to further investigate the effect of diet on fatty acid production. 
After 11 months, a necropsy was performed to collect various samples from the birds, including 
the ovaries. The ovarian tissues were then analyzed to determine the concentrations of PUFA and 
SCFA in each sample. A simple lipid extraction was performed first to separate the lipids from the 
other components of the sample. Fatty acid methyl ester (FAME) preparation was then performed 
to prepare the samples for gas chromatographic analysis. By performing gas chromatography, the 
concentrations of fatty acids in each sample was determined and the data was normalized to protein 
content. An enzyme linked immune-sorbent assay (ELISA) was performed on the same ovarian 
samples to measure the levels of prostaglandin in each sample. This data was normalized to the 
protein content. In order to better understand the synthesis and distribution of SCFA in the body, 
the ceca were also analyzed using the same method as the ovaries previously discussed. These 
concentrations were then compared to the concentrations of the SCFA in the ovaries. The analysis 
revealed that hens that were fed a flaxseed-supplemented diet had higher levels of OM3 PUFA 
compared to OM6 PUFA in both the ovaries and the ceca. The concentrations of SCFA were also 
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slightly increased in the ovaries and ceca of flax-fed hens compared to the control group. More 
significantly than the effect of diet, this analysis showed that ovarian cancer results in a significant 
increase of SCFA concentrations in the ovaries and the ceca. These observations give us insight 
into the possible role of flaxseed in modulating metabolic activity through an upregulation of 
SCFA and PUFA in the ovaries.  
Table 1: Content of flaxseed diets 
Control  15% Whole Flax 
(WF) 
5% Flax Oil 
(FXO) 
15% Defatted Flax Meal 
(DFM) 
 
 SDG + ALA ALA SDG 
Omega 
3/6 
 Omega 3 Rich Omega 3 Rich Low Omega 3 
No SDG  High SDG No SDG High SDG 
 
III. Material and Methods 
Lipid Extraction 
Ovarian tissues were collected and 200 mg were aliquoted into glass test tubes. Samples were 
homogenized with 1mL of homogenate buffer (20x Protease Inhibitor and 10mM Tris Buffer) 
using Tissue Tearor Homogenizer (Biospec Products, Inc. USA) on dry ice. 200 µl of the samples 
were transferred to new test tubes, and the rest was stored at -20°C until further use. To the 200 
µl, 30 µg/mL heptadecanoic acid (C17:0) was added as an internal standard. These samples were 
then extracted twice using chloroform and water, and were centrifuged at 3400 rpm, for 10 min., 
at 4°C, between each extraction. The organic layer was removed and stored at -20°C until further 
use. This procedure was also used to extract lipids from the ceca, but 2 mL of homogenate was 
used, rather than 1 due to increased thickness of these samples. 
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Fatty Acid Methyl Ester (FAME) Preparation 
Extracted samples were dried under ultra-pure nitrogen (UPN), and acetyl chloride and methanol 
was used to convert fatty acids to methyl esters. The oxygen was then flushed out of the samples 
using UPN, and the samples were incubated in a dry over for 1 hr. Dried samples were then taken 
out to cool, and fatty acids were extracted using hexane and water. The samples were centrifuged 
at 3400 rpm, for 10 min, at 4°C. The hexane layer was removed and dried once again under UPN. 
125 µl of hexane was then used to re-suspend the dried samples, and the resuspension was 
transferred to gas chromatography vials. The vials were capped and stored at  -20°C until further 
use. The same procedure was used to prepare the ceca for gas chromatographic analysis.  
Gas Chromatography 
Quantification of FAME was performed using gas chromatography with flame ionization detection 
(GC-FID). GC was performed on a Shimadzu GC-2010 Gas Chromatograph equipped with a 
Supelco Omegawax 250 capillary column (30 m, 0.25 mm ID, 0.25 µm film thickness).  Samples 
were injected into a split injector held at 250°C and with helium carrier gas running at a column 
flow of 1.25 mL/min with a 100:1 split. Analytes were detected using a flame ionization detector 
held at 260°C. All data were acquired and analyzed Shimadzu Chromatography Data System. All 
automatic peak assignments and integrations were manually verified. 
Protein Analysis 
The remainder of the homogenized samples saved during the lipid extraction phase of the 
experiment was thawed and used in a protein assay to normalize the data collected from the GC. 
First, a standard curve was established using known amounts of protein (BSA [2mg/mL]), diluted 
with buffer SDS buffer (0.1% in 1x PBS) in the first two columns of a 96-well plate, using the 
amounts shown below in Table 2.  
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Table 2: BSA Protein Assay standards performed in replicates. Ratios denote protein (BSA) to buffer (0.1% SDS in 1x PBS) 
protein:buffer 
(µL) 
Column 1 Column 2 
(replicate) 
A 0:10 0:10 
B 1:9 1:9 
C 2:8 2:8 
D 3:7 3:7 
E 4:6 4:6 
F 6:4 6:4 
G 8:2 8:2 
H 10:0 10:0 
 
After the protein and buffer was pipetted to create the standard curve, 2 µl of each unknown ovary 
samples were added in triplicates in the subsequent wells with 8 µl of 0.1% SDS buffer in 1x PBS. 
Enough of a 50:1 dilution of BCA protein assay reagents A and B (Thermo Fischer Scientific, 
USA) was then made to add 200 µl of the mixture to each well, including both the standards and 
unknown samples. After the AB reagent mixture has been added to each of the wells, the plate is 
incubated in the Synergy plate reader with slow shaking at 37°C for 30 min. Following the 
incubation, the plate was read at 562 nm, and absorbance values are used to calculate the 
concentration of protein in each sample, which is in turn used to determine the concentration of 
fatty acid/mg of protein. The R2 value determined by the accuracy of the standard curve should be 
greater than 0.99 to yield the most accurate results. For the ceca, the samples were sonicated prior 
to increase liquefaction.  
Enzyme Linked Immuno-Sorbent Assay (ELISA) 
The same ovaries previously used were aliquoted again with 200 mg in glass test tubes. Samples 
were homogenized with 0.5 mL of homogenate buffer (20x Protease Inhibitor and 10mM Tris 
Buffer) using Tissue Tearor Homogenizer (Biospec Products, Inc. USA) on dry ice. These samples 
were then centrifuged at 3400 rpm, for 10 min., at 4°C, and the supernatant was collected. The 
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samples were then set aside for use in the ELISA kit (Cayman Chemical, USA) and the instructions 
provided in the kit were followed. First the ELISA and wash buffers were prepared. One vial of 
10x ELISA buffer was diluted with 90 mL of UltraPure (UP) water. 2.5 mL of the 400x wash 
buffer was diluted to 1 mL with UP water and 0.5 mL of Polysorbate 20 was added. The standards 
were then prepared by adding 100µL of the ELISA buffer to the provided ELISA standard. Eight 
glass test tubes were then labelled and serial dilutions were performed as follows:  
 
Acetylcholineesterase (AChE) Tracer and Antibody were then prepared by adding 6 mL of ELISA 
buffer to each of the 100 dtn vials. The 96-well plate was provided pre-coated with antibody. A 
sample of the plate format is shown below: 
First, 100 µL of ELISA buffer was added to the NSB wells, and 50 µL of ELISA buffer was added 
to the B0 wells. 50 µL of the standards were then added in their coordinating wells beginning with 
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S8 and working up to S1. 50 µL of the samples that were previously prepared were then added to 
the remaining wells in duplicate. 50 µL of AChE Tracer was then added to all the wells except the 
TA and the Blk wells and 50 µL of AChE Antibody was added to each well except the TA, NSB, 
and Blk wells. The plate was then covered, and incubated for 18 hours at 4°C. After 18 hours the 
wells were emptied and washed 10 times with wash buffer. The 100 dtn Ellman’s reagent was 
reconstituted in 20 mL of UP water right before use. 200 µL of this reagent was added to each 
well. 5 µL of AChE Tracer was added to the TA well, and the plate was incubated in the Synergy 
plate reader with slow shaking at 37°C for 60 minutes. The plate was read at 420 nm, and the 
concentrations of prostaglandin E2 (PGE2) were then calculated. A protein assay was again 
performed to normalize the data.  
 Statistical Analysis 
Comparison of values between groups was performed by two-way ANOVA, using Tukey- 
Kramer’s Post Hoc, p < 0.5 to identify significant values. 
IV. Results 
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Figure 1: Concentrations of 
protein in ovarian tissues 
A protein assay was used to 
determine the amount of protein in 
each sample. This was then used to 
normalize the gas chromatography 
data to determine the amount of 
fatty acid in each microgram of 
protein. The protein assay was 
performed in triplicates. R2 = 0.996. 
Error bars represent SEM.  
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Figure 2: Concentrations of 
protein in ceca compared to 
ovarian tissues 
A protein assay was used to 
determine the amount of protein in 
each ceca sample. This was then used 
to normalize the gas chromatography 
data to determine the amount of fatty 
acid in each microgram of protein. 
The protein content in the ceca 
samples were then compared to the 
protein content in the ovariean 
samples. The data was normalized to 
the amount of protein in the ovaries 
of healthy, control-fed hens. The 
protein assay was performed in 
triplicates. R2 = 0.998. Error bars 
represent SEM.  
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Figure 3: Whole Flax v. Control 
PUFA in cancerous ovarian 
tissues 
Gas chromatographic analysis was 
performed to determine the 
concentrations of PUFA in ovarian 
tissues collected from hens fed 6 
various diets. C4-C24 FAME mix 
was used to identify the fatty acids 
(shown in the first chromatograph). 
The next chromatograph compares 
whole flax (black) with control 
(red). C17:0 was used as an internal 
standard. The data was normalizaed 
using a protein assay, and the effects 
of the diet and disease on the ratio of 
OM3 to OM6 PUFA in the ovaries 
was examined. Error bars represent 
SEM. Tukey-Kramer’s Post Hoc, 
p<0.05.  
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Figure 4: Effect of diet and disease 
on the conversion of ALA to DHA 
ALA has various fates once it is 
introduced to the body. One of these 
involves being converted into longer 
chain fatty acids, such as EPA and 
DHA, by desaturase and elongase 
enzymes. A.) Compares the levels of 
ALA across all 6 diets in normal and 
diseased birds B.) Compares the 
levels of EPA alone. C.) Compares 
the levels of DHA alone. D.) Displays 
a chromatograph zoomed in on the 
peak representing DHA to observe 
how much DHA has been produced 
in WF-fed, healthy birds (red), WF-
fed, cancerous birds (black), control-
fed, healthy birds (blue), and control-
fed, cancerous birds (green). The 
error bars indicate SEM. Tukey-
Kramer’s Post Hoc, p < 0.05.  
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Figure 5: Effect of diet and 
cancer on levels of prostaglandin 
E2 and arachidonic acid in the 
ovaries 
ELISA was performed on ovaries 
to also measure the levels of 
PGE2. R2 = 0.99. Arachadonic 
acid concentrations were 
determined using gas 
chromatography. Data was 
quantified, and compared between 
the various diets and between 
healthy and diseased hens. Both of 
these concentrations were 
normalized to protein content. 
Error bars represent SEM.  
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Figure 6: Ratio of OM3 to OM6 PUFA in hen ceca 
PUFA concentrations were determined by gas chromatography. The levels of a OM3 and OM6 PUFA 
were quantified and the effects of diet and disease were then observed. Error bars represent SEM.  
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Figure 7: Diet and carcinogenic effects on butyric acid (C4:0) composition in ovarian tissues 
SCFA concentrations were determined by gas chromatography. The levels of a common SCFA, butyric 
acid (C4:0), were quantified and compared between the six different diets and between healthy and 
diseased hens. Error bars represent SEM. Tukey-Kramer’s Post Hoc, p < 0.05. 
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Figure 8: Effect of diet and cancer on C4:0 production in the ceca compared to levels in the ovaries 
Butyric acid (C4:0) concentrations in chicken ceca were determined using gas chromatography. The 
levels were quantified and first compared between whole flax and control fed hens, and then between 
healthy birds and birds with advanced stage ovarian cancer. The data was normalized to protein content.  
The concentrations of C4:0 in the ceca were then compared to the data collected from the ovarian 
samples. Error bars represent SEM.  
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V. Discussion 
The six diets explored in this study were designed to test the hypothesis that OM3 PUFA 
and SCFA are upregulated in the ovaries as a result of a flaxseed-supplemented diet, and that this 
upregulation may be one mechanism in which flaxseed can work to regulate metabolic activity. 
Figure 1 indicates that protein concentrations in the ovaries are not affected by neither diet nor 
disease. Figure 2 shows that diet and disease also have no effect on the protein content in the ceca. 
Although no effect of diet or disease was observed on either sample, the ceca samples had a much 
greater protein content compared to the ovarian samples.  
In Figure 3 it is shown that flax-supplemented diets slightly increase the mean levels of 
OM3:OM6 PUFA compared to control fed birds in both healthy and diseased states, although the 
quantities are not significantly different. This data also indicates that in control fed hens (hens that 
were not fed flaxseed as a source of OM3 PUFA), the disease may affect the ability to produce 
DHA shown by significantly reduced levels in the birds with ovarian cancer. Figure 4 explored 
the efficiency of the conversion of ALA to the longer chain PUFA- EPA and DHA. The data show 
that birds with ovarian cancer that are fed a whole flax-supplemented diet more readily convert 
ALA to DHA than healthy birds and diseased birds fed a control diet. Levels of ALA vary across 
the diets but are lowest in the control and corn oil-fed hens, and levels of EPA remain mostly 
consistent. Next, the levels of PGE2 were examined in relation to the levels of AA. Figure 5 
indicates that no correlation was observed between these values, however, the levels of PGE2 were 
consistent with the trends observed in the ratios of OM3:OM6, indicating that when OM3 PUFA 
are increased, less PGE2 is able to be synthesized. It was also noted that AA was significantly 
reduced in whole-flax fed hens. The ratios of OM3:OM6 PUFA in the ceca were also determined, 
and in Figure 6, it was observed that a whole-flax diet significantly increased the levels of OM3, 
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in particular DHA. It was also shown in this data that the levels of DHA in the ceca, which average 
between 50 and 70 mg/mL per μg protein, are significantly higher compared to the levels in the 
ovaries, which are only between 5 and 10 mg/mL per μg protein. In addition, this data confirmed 
that disease state does in fact have an effect on DHA production because in the ovaries of control 
fed hens, birds with ovarian cancer had significantly less DHA than healthy birds (shown in Figure 
1), but the DHA levels in the ceca had not been affected.  
Butyric acid was increased in the oil based diets and flax-supplemented diets, although the 
values were not significantly different. Disease state showed to have a greater effect, as observed 
in Figure 7, butyric acid was significantly higher in healthy birds than ones with ovarian cancer, 
regardless of which diet the hen was fed. This observation signifies a possible impairment in 
enteric SCFA production and/or intra-ovarian tissue metabolism. To further explore whether this 
was an impairment in SCFA production or function, the levels of butyric acid were measured 
where they are produced, in the colon. In Figure 8, it is shown that the levels of butyric acid 
observed in the ovaries are consistent with the production in the ceca, showing a slight increase in 
the birds fed a whole-flax diet compared to control, and a significant decrease in birds with 
advanced stage ovarian cancer compared to healthy birds. However, the levels of butyric acid were 
higher in the ovaries than in the ceca, indicating that they likely do not stay in the ceca long before 
moving to the liver to be stored and/or to the target organ.  
VI. Conclusion 
Previously, our lab has shown that a flaxseed-supplemented diet reduces both the incidence 
and severity of ovarian cancer. This study aimed to investigate the possible mechanisms in which 
flaxseed, when consumed, is able to regulate metabolic activity and gene expression in ovarian 
cancer by first, exploring the role of the OM3 component of flaxseed. Because OM3 and OM6 
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PUFA cannot be produced by the body, production of these fatty acids is solely dependent on 
dietary intake. Gas chromatographic analysis revealed that ratios of OM3:OM6 PUFA are slightly 
elevated in the ovaries of birds fed a flaxseed-supplemented diet when compared to the control 
group. This data was consistent with the concentrations of AA measured in the ovaries, which 
were significantly reduced in flax-fed hens. This is significant because OM3 and OM6 PUFA 
compete to use the same elongase and desaturase enzymes. At higher levels of OM3, more DHA 
can be produced from ALA, rather than AA from LA, which would lead to increased prostaglandin 
synthesis. PGE2 levels were measured using ELISA, and were found to be slightly reduced in hens 
that were fed a whole flax or flax oil diets compared to the control group, which is consistent with 
the trends observed in the ratios of OM3:OM6, indicating that when OM3 PUFA are increased, 
less PGE2 is able to be synthesized. This data is also consistent with the levels of AA measured in 
the ovarian samples. These observations further indicate that by increasing levels of OM3 in the 
ovaries, a flaxseed-supplemented diet inhibits or significantly reduces the enzymatic activity 
available to convert LA into AA, which is required to produce PGE2. By decreasing the levels or 
PGE2, the negative side effects of inflammation and oxidative stress are also prevented. 
In addition to a reduced overall ratio of OM3:OM6, the birds in the control group that were 
not fed a flaxseed-supplemented diet had slightly lower amounts of DHA in their ovaries compared 
to the flax-fed birds, and significantly lower amounts of DHA if the birds had ovarian cancer. 
However, the same effects were not observed in the ceca, indicating that the cancer likely had a 
direct effect on the ability for these hens to convert ALA to DHA at the ovarian tissue level. The 
levels of DHA in the flax-fed hens did not seem to be affected by the disease in the ovaries or the 
ceca, which suggests that hens that were fed a flaxseed-supplemented diet with ovarian cancer are 
more likely to benefit from the anti-cancer effects of DHA, which has greater anti-inflammatory 
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and antioxidant effects than ALA alone. Increases in DHA might suggest that flaxseed increases 
DHA by increasing Δ6-desaturase activity. The consistent levels of EPA that were observed are 
likely due to the fact that desaturase enzymes work very slowly to produce EPA from ALA, but 
once formed, EPA is very quickly elongated and converted to DHA by Δ6-desaturase enzymes, 
which contributes to why levels of DHA are consistently higher than ALA or EPA.  
This study also investigated the role of flaxseed as a dietary fiber, which can be fermented 
in the gut to produce SCFA, specifically butyric acid. The flaxseed-supplemented diet exhibited a 
slight increase in butyric acid, which has been found to act as an HDAC inhibitor, acting on various 
genes responsible for improving cellular immunity, protecting against oxidative stress, regulating 
mitochondrial activity, and protecting the body from various diseases. The decreased level of 
SCFA observed in ovarian tumors as compared to healthy ovaries indicates impaired enteric 
production of SCFA (from dietary fibers) and/or enhanced oxidation of SCFA in ovarian tumors. 
This would reduce the effect of SCFA as HDAC inhibitors, transcriptional modulators, and anti-
inflammatory molecules, in tumors versus healthy tissues. To further investigate the reduction of 
SCFA seemingly to be caused by ovarian tumors, butyric acid was also measure in the ceca where 
it is produced. The effects of diet and disease on the levels of butyric acid in the ceca was consistent 
with the effects observed in the ovaries- the birds fed a whole-flax diet had slightly higher levels 
of butyric acid in the ceca compared to the control group, and there was a significant decrease in 
butyric acid in birds with advanced stage ovarian cancer. This suggests that the cancer does not 
necessarily decrease the fermentation of SCFA or the activity of the gut microbiota, but instead, 
might increase the oxidation of SCFA in ovarian cancer cells because SCFA can readily diffuse 
across the mitochondrial membrane, in contrast to longer chain fatty acids, to be implemented as 
an energy source. If cancer cells are more quickly using up the stores of SCFA, this would 
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contribute to why the significant decrease in butyric acid is observed in both the ceca and ovaries 
collected from hens with ovarian cancer. Due to the significant increase in butyric acid levels 
measured in the ovaries compared to the ceca, it is concluded that the SCFA do not remain in the 
ceca for very long following fermentation, and are quickly transported to the liver to be stored 
and/or transported to the target organ. 
Overall, this study suggests that dietary flaxseed could upregulate the conversion of ALA 
to DHA in ovarian cancer through an increase of OM3 PUFA over OM6. In addition, this increase 
in OM3:OM6 PUFA ratio contributes to a decrease in AA, and as a result, a slight decrease in 
PGE2. Through fermentation in the gut, the dietary fibers of flaxseed slightly increase the levels 
of butyric acid in the ovaries. However, these levels are significantly reduced in ovarian cancer, 
suggesting that SCFA are used as an energy source for ovarian cancer cells. These observations in 
OM3 PUFA and SCFA in the ovaries produced as a result of a flaxseed supplemented diet could 
provide insight into two possible mechanisms in which dietary flaxseed regulates metabolic 
activity and gene expression to prevent or reduce the severity of ovarian cancer.  
VII. Future Directions 
Future studies include further exploration into the role of SCFA by measuring their 
concentrations in the liver to acquire a better understanding of SCFA storage and movement within 
the body and increasing the sample size of the experiments already performed in order to obtain 
the most accurate results. Another future aim would include investigating the specific effects of 
flaxseed on the desaturase and elongase enzyme activity.  
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